Saurashtra News

Fragile X Syndrome Pipeline, Clinical Trials and NDA Approvals 2023 (Updated)

 Breaking News
  • No posts were found

Fragile X Syndrome Pipeline, Clinical Trials and NDA Approvals 2023 (Updated)

September 15
20:01 2023
Fragile X Syndrome Pipeline, Clinical Trials and NDA Approvals 2023 (Updated)

DelveInsight’s, “Fragile X Syndrome Pipeline Insight, 2023,” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Fragile X Syndrome pipeline landscape. It covers the Fragile X Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Fragile X Syndrome Pipeline Report

  • DelveInsight’s Fragile X Syndrome pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Fragile X Syndrome treatment.
  • The leading companies working in the Fragile X Syndrome Market include Zynerba Pharmaceuticals, Tetra Therapeutics, Autifony Therapeutics, Prilenia Therapeutics, Alcobra Ltd., Seaside Therapeutics, Inc., Marinus Pharmaceuticals, Novartis Pharmaceuticals, Neuren Pharmaceuticals, Hoffmann-La Roche, Healx, Nova Mentis, Lysogene, Actinogen, Prilenia Therapeutics, Confluence Pharmaceuticals, Sentinel Oncology, and others.
  • Promising Fragile X Syndrome Pipeline Therapies in the various stages of development include Psilocybin, 1.5 mg, MG01CI extended-release tablet, Zatolmilast/ BPN14770, ZYN002 – transdermal gel, arbaclofen, AFQ056, Ganaxolone, STX209, and others.
  • In February 2023, Tetra Discovery Partners announced a study of Phase 3 Clinical Trials for Zatolmilast/ BPN14770. This is an open-label extension (OLE) study for subjects completing one of two double-blind clinical trials with BPN14770, Study BPN14770-CNS-301(in adult males) and Study BPN14770-CNS-204 (in adolescent males).
  • In May 2023, Nova Mentis Life Sciences Corp. announced a study of Phase 2 Clinical Trials for Psilocybin, 1.5 mg. The overall objective of this study is to assess the feasibility of low-dose psilocybin as a therapeutic option for individuals living with FXS and to improve diagnostic parameters of FXS, as well as therapeutic responses with the use of biomarkers.

 

Request a sample and discover the recent advances in Fragile X Syndrome Treatment Drugs @ Fragile X Syndrome Pipeline Report

 

The Fragile X Syndrome pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Fragile X Syndrome drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Fragile X Syndrome clinical trial landscape.

 

Fragile X Syndrome Overview

Fragile X syndrome (FXS) is a genetic disorder. FXS is caused by changes in a gene that scientists called the fragile X mental retardation 1 (FMR1) gene when it was first discovered. The FMR1 gene usually makes a protein called fragile X mental retardation protein (FMRP). FMRP is needed for normal brain development.

 

Find out more about Fragile X Syndrome Treatment Drugs @ Drugs for Fragile X Syndrome Treatment

 

Fragile X Syndrome Emerging Drugs Profile

  • Zatolmilast: Tetra Discovery Partners
  • Zygel: Zynerba Pharmaceuticals
  • Pridopidine: Prilenia Therapeutics

 

Fragile X Syndrome Pipeline Therapeutics Assessment

There are approx. 20+ key companies which are developing the therapies for Fragile X Syndrome. The Fragile X Syndrome companies which have their Fragile X Syndrome drug candidates in the most advanced stage, i.e. Phase III include Zynerba Pharmaceuticals and others.

 

Learn more about the emerging Fragile X Syndrome Pipeline Therapies @ Fragile X Syndrome Clinical Trials Assessment

 

Scope of the Fragile X Syndrome Pipeline Report

  • Coverage- Global
  • Encephalopathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Encephalopathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Fragile X Syndrome Companies- Zynerba Pharmaceuticals, Tetra Therapeutics, Autifony Therapeutics, Prilenia Therapeutics, Alcobra Ltd., Seaside Therapeutics, Inc., Marinus Pharmaceuticals, Novartis Pharmaceuticals, Neuren Pharmaceuticals, Hoffmann-La Roche, Healx, Nova Mentis, Lysogene, Actinogen, Prilenia Therapeutics, Confluence Pharmaceuticals, Sentinel Oncology, and others.
  • Fragile X Syndrome Pipeline Therapies- Psilocybin, 1.5 mg, MG01CI extended-release tablet, Zatolmilast/ BPN14770, ZYN002 – transdermal gel, arbaclofen, AFQ056, Ganaxolone, STX209, and others.

 

Dive deep into rich insights for new drugs for Fragile X Syndrome Treatment, Visit @ Fragile X Syndrome Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Fragile X Syndrome: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Fragile X Syndrome– DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Fragile X Syndrome Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Zatolmilast: Tetra Discovery Partners
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. HLX-0201: Healx
  14. Drug profiles in the detailed report…..
  15. Preclinical Stage Products
  16. Pridopidine: Prilenia Therapeutics
  17. Drug profiles in the detailed report…..
  18. Inactive Products
  19. Fragile X Syndrome Key Companies
  20. Fragile X Syndrome Key Products
  21. Fragile X Syndrome- Unmet Needs
  22. Fragile X Syndrome- Market Drivers and Barriers
  23. Fragile X Syndrome- Future Perspectives and Conclusion
  24. Fragile X Syndrome Analyst Views
  25. Fragile X Syndrome Key Companies
  26. Appendix

 

For further information on the Fragile X Syndrome Pipeline therapeutics, reach out to Fragile X Syndrome Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting

Related Articles